biostudies-literatureUnknown20(32)Swami UAstellas Pharma<b>Aim:</b> Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC.<b>Patients & methods:</b> This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US.<b>Results:</b> Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone.<b>Conclusion:</b> Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC.Future oncology (London, England)2467-2480https://www.ebi.ac.uk/biostudies/studies/S-EPMC11520573biostudies-literatureTreatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States.PMC11520573Ramaswamy KSwami UBunner SHYoung CGupta SChastek BDiessner BEl Chaar NHong AXie BfalseTreatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States.<b>Aim:</b> Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC.<b>Patients & methods:</b> This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US.<b>Results:</b> Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone.<b>Conclusion:</b> Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC.2024-01-01T00:00:00Z20242025-04-04T13:19:46.29Z2025-04-04T13:19:46.29ZS-EPMC115205733907361010.1080/14796694.2024.2373681